Literature DB >> 8229833

Ca2+ channel modulating effects of heparin in mammalian cardiac myocytes.

L Lacinova1, L Cleemann, M Morad.   

Abstract

1. The effect of heparin on L-type Ca2+ channels in rabbit, rat and guinea-pig cardiac myocytes was studied using the whole-cell patch clamp method. 2. Sodium salts of heparin uniformly suppressed the Ca2+ current, ICa, independent of their molecular weight, in the rat and guinea-pig ventricular and rabbit atrial myocytes. The suppression of ICa by heparin was dose dependent and reached its maximum, about 30%, around 10 microM. Heparin did not alter the voltage-dependence or the steady-state inactivation properties of ICa. These effects were specific to heparin as another polysaccharide, dextran, failed to have any effect on ICa. 3. The suppressive effect of heparin was not diminished when [Ca2+]o was increased to 10 mM, or when Ba2+ was the charge carrier through the Ca2+ channel. 4. Spectrophotometric assays showed that heparin-induced changes in [Ca2+]o generally were too small to alter ICa significantly. 5. In myocytes buffered with 0.1 mM EGTA, the suppressive effect of heparin was more prominent on the inactivating than on the maintained component of ICa. 6. When extracellular Na+ was replaced by Cs+, the heparin suppressive effect was accompanied by a 10 mV shift of both the voltage dependence of activation and the steady-state inactivation parameters toward more negative potentials. 7. When both Mg2+ and Na+ were omitted from the bathing solutions, the suppressive effect of heparin was significantly enhanced such that almost 80% of the current was blocked. 8. In Cs(+)-based solutions 10 mM [Mg2+]o suppressed ICa by about 70% and heparin partially relieved this block. Heparin, however, did not counteract the Mg(2+)-induced suppression of ICa in Na(+)-based solution. 9. Extracellularly applied heparin did not alter the isoprenaline-induced enhancement of ICa or interfere with the blocking effect of phorbol esters on ICa. 10. Heparin thus appears to interfere with the permeation of Ca2+ through the channel by a mechanism regulating the Ca(2+)-induced inactivation of the Ca2+ channel. Na+ and Mg2+ appear to alter the kinetics and the magnitude of the suppressive effect of heparin on the Ca2+ channel, suggesting an interaction of these cations with either the Ca2+ or the heparin-binding sites of the channel.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8229833      PMCID: PMC1175425          DOI: 10.1113/jphysiol.1993.sp019672

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  23 in total

1.  A uniform enzymatic method for dissociation of myocytes from hearts and stomachs of vertebrates.

Authors:  R Mitra; M Morad
Journal:  Am J Physiol       Date:  1985-11

Review 2.  Magnesium ions in cardiac function. Regulator of ion channels and second messengers.

Authors:  R E White; H C Hartzell
Journal:  Biochem Pharmacol       Date:  1989-03-15       Impact factor: 5.858

3.  Phosphorylation of chick heart muscarinic cholinergic receptors by the beta-adrenergic receptor kinase.

Authors:  M M Kwatra; J L Benovic; M G Caron; R J Lefkowitz; M M Hosey
Journal:  Biochemistry       Date:  1989-05-30       Impact factor: 3.162

4.  Quantitative similarity of zinc and calcium binding to heparin in excess salt solution.

Authors:  J Mattai; J C Kwak
Journal:  Biophys Chem       Date:  1988-09       Impact factor: 2.352

5.  Modulation by polyelectrolytes of canine cardiac microsomal calcium uptake and the possible relationship to phospholamban.

Authors:  Z C Xu; M A Kirchberger
Journal:  J Biol Chem       Date:  1989-10-05       Impact factor: 5.157

6.  Inhibition of beta-adrenergic receptor kinase prevents rapid homologous desensitization of beta 2-adrenergic receptors.

Authors:  M J Lohse; R J Lefkowitz; M G Caron; J L Benovic
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

7.  Heparin-induced aggregation of lymphoid cells.

Authors:  A L Thurn; C B Underhill
Journal:  J Cell Physiol       Date:  1986-03       Impact factor: 6.384

8.  A diacylglycerol analogue reduces neuronal calcium currents independently of protein kinase C activation.

Authors:  P Hockberger; M Toselli; D Swandulla; H D Lux
Journal:  Nature       Date:  1989-03-23       Impact factor: 49.962

9.  Heparin uncouples alpha 2-adrenoceptors from the Gi-protein in membranes of human platelets.

Authors:  B Willuweit; K Aktories
Journal:  Biochem J       Date:  1988-02-01       Impact factor: 3.857

10.  Negative surface charge density near heart calcium channels. Relevance to block by dihydropyridines.

Authors:  R S Kass; D S Krafte
Journal:  J Gen Physiol       Date:  1987-04       Impact factor: 4.086

View more
  4 in total

1.  Modulation of Ca2+ channels, charge movement and Ca2+ transients by heparin in frog skeletal muscle fibres.

Authors:  M Martínez; M C García; J M Farías; H Cruzblanca; J A Sánchez
Journal:  J Muscle Res Cell Motil       Date:  1996-10       Impact factor: 2.698

2.  Extracellular heparin inhibits Ca2+ transients and contraction in mammalian cardiac myocytes.

Authors:  M C Garcia; J A Sanchez; V K Sharma; S S Sheu
Journal:  Pflugers Arch       Date:  1995-11       Impact factor: 3.657

3.  Nonanticoagulant heparin reduces myocyte Na+ and Ca2+ loading during simulated ischemia and decreases reperfusion injury.

Authors:  William H Barry; Xiu Q Zhang; Michael E Halkos; Jakob Vinten-Johansen; Noriko Saegusa; Kenneth W Spitzer; Nobuhiro Matsuoka; Michael Sheets; Narayanam V Rao; Thomas P Kennedy
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-10-23       Impact factor: 4.733

4.  Perlecan/Hspg2 deficiency impairs bone's calcium signaling and associated transcriptome in response to mechanical loading.

Authors:  Shaopeng Pei; Sucharitha Parthasarathy; Ashutosh Parajuli; Jerahme Martinez; Mengxi Lv; Sida Jiang; Danielle Wu; Shuo Wei; X Lucas Lu; Mary C Farach-Carson; Catherine B Kirn-Safran; Liyun Wang
Journal:  Bone       Date:  2019-11-09       Impact factor: 4.398

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.